CFO of Apogee Therapeutics (APGE) sells 2,000 shares under 10b5-1 plan

Rhea-AI Filing Summary

Apogee Therapeutics, Inc. Chief Financial Officer Jane Henderson executed pre-planned open-market sales of company common stock. On May 1, 2026, she sold a total of 2,000 shares in three transactions at reported weighted average prices between about $81 and $83 per share, under a Rule 10b5-1 trading plan adopted on September 2, 2025. Following these sales, she directly holds 173,371 shares of Apogee common stock.

Insider Trade Summary 10b5-1

Net Seller: 2,000 shares ($164,080)

Net Sell 3 txns

Insider Henderson Jane

Role Chief Financial Officer

Sold 2,000 shs ($164K)

Type	Security	Shares	Price	Value
Sale	Common Stock	811	$81.02	$66K
Sale	Common Stock	900	$82.60	$74K
Sale	Common Stock	289	$83.16	$24K

Holdings After Transaction: Common Stock — 174,560 shares (Direct, null)

Footnotes (1)

1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 2, 2025. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $80.640 to $81.260, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $82.040 to $82.995, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $83.090 to $83.190, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

Key Figures

Total shares sold: 2,000 shares Shares sold at $81.02: 811 shares at $81.02/share Shares sold at $82.60: 900 shares at $82.60/share +3 more

6 metrics

Total shares sold 2,000 shares Open-market sales on May 1, 2026 by CFO Jane Henderson

Shares sold at $81.02 811 shares at $81.02/share One of three reported sale tranches

Shares sold at $82.60 900 shares at $82.60/share One of three reported sale tranches

Shares sold at $83.16 289 shares at $83.16/share One of three reported sale tranches

Post-transaction holdings 173,371 shares Direct ownership after reported sales

Rule 10b5-1 plan adoption date September 2, 2025 Plan governing execution of the reported trades

Key Terms

Rule 10b5-1 trading plan, weighted average price, open-market sale

3 terms

Rule 10b5-1 trading plan regulatory

"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 2, 2025."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported above is a weighted average price. The shares were sold in multiple transactions..."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Henderson Jane

(Last) (First) (Middle)

C/O APOGEE THERAPEUTICS, INC.

221 CRESCENT ST., BLDG. 17, STE. 102B

(Street)

WALTHAM MASSACHUSETTS 02453

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Apogee Therapeutics, Inc. [ APGE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/01/2026		S(1)		811	D	$81.02(2)	174,560	D
Common Stock	05/01/2026		S(1)		900	D	$82.6(3)	173,660	D
Common Stock	05/01/2026		S(1)		289	D	$83.16(4)	173,371	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 2, 2025.

2. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $80.640 to $81.260, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.

3. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $82.040 to $82.995, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

4. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $83.090 to $83.190, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

	/s/ Matthew Batters, as attorney-in-fact for Jane Pritchett Henderson	05/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Apogee Therapeutics (APGE) report for Jane Henderson?

Apogee reported that CFO Jane Henderson sold 2,000 shares of common stock in open-market transactions. These sales occurred on May 1, 2026 in three separate trades at weighted average prices in the low-$80 range per share.

At what prices did Apogee Therapeutics (APGE) CFO sell her shares?

Jane Henderson’s Form 4 shows weighted average sale prices of $81.02, $82.60, and $83.16 per share. Footnotes note that each reported price reflects multiple trades within narrow ranges around those levels during the trading day.

How many Apogee Therapeutics (APGE) shares does the CFO hold after the sale?

After these transactions, CFO Jane Henderson directly holds 173,371 shares of Apogee common stock. The Form 4 lists this figure as her direct ownership following the reported open-market sales on May 1, 2026.

Was the Apogee Therapeutics (APGE) CFO sale under a Rule 10b5-1 plan?

Yes. A footnote states the transaction was executed under a Rule 10b5-1 trading plan adopted on September 2, 2025. Such plans pre-schedule trades, indicating the timing was set in advance rather than decided on the trade date.

How many Apogee Therapeutics (APGE) share sale transactions were reported?

The Form 4 reports three separate open-market sale transactions, all on May 1, 2026. They cover 811 shares at $81.02, 900 shares at $82.60, and 289 shares at $83.16, totaling 2,000 shares of Apogee common stock sold.